Skip NavigationSkip to Content
Return Return to Search Results

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

  1. Author:
    Takebe, Naoko
    Naqash, Abdul Rafeh
    Coyne, Geraldine O'Sullivan
    Kummar, Shivaani
    Do, Khanh
    Bruns, Ashley
    Juwara,Lamin
    Zlott, Jennifer
    Rubinstein, Larry
    Piekarz, Richard
    Sharon, Elad
    Streicher, Howard
    Mittra, Arjun
    Miller, Sarah B.
    Ji,Jay
    Wilsker,Deborah
    Kinders,Robert
    Parchment,Ralph
    Chen,Li
    Chang,Ting-Chia
    Das,Biswajit
    Mugundu, Ganesh
    Doroshow, James H.
    Chen, Alice P.

  2. Author Address

    NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.NCI, Ctr Canc Res, Bethesda, MD 20892 USA.Frederick Natl Lab Canc Res, Clin Monitoring Res Program, Clin Res Directorate, Frederick, MD USA.Frederick Natl Lab Canc Res, Clin Pharmacodynam Biomarkers Program, Appl Dev Res Directorate, Frederick, MD USA.Frederick Natl Lab Canc Res, Mol Characterizat Lab, Frederick, MD USA.AstraZeneca, Clin Pharmacol, Waltham, MA USA.
    1. Year: 2021
    2. Date: Apr 16
  2. Journal: CLINICAL CANCER RESEARCH
  3. AMER ASSOC CANCER RESEARCH,
    1. 27
    2. 14
    3. Pages: 3834-3844
  5. Type of Article: Article
  6. ISSN: 1078-0432
  1. Abstract:

    Purpose: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report results for once-daily adavosertib.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1078-0432.CCR-21-0329
  3. PMID: 33863809
  4. View record in Web of Science®
  5. WOS: 000674703200007

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel